molecules of the month


oral, non-steroidal SERD/SERM

approved for ER+, HER2-, mESR1 adv./metastatic BC

degrades ERɑ in dose-dependent manner

FDA approval, January 27, 2023

Eisai, Tokyo, JP (Stemline/Menarini)

elacestrant chemical structure oral, non-steroidal SERD/SERM - Eisai, Tokyo, JP (Stemline/Menarini)
4 mins read

What is it? Elacestrant (Orserdu) is an oral, selective estrogen receptor modulator and degrader (SERM/SERD) that was recently approved for ER-positive, HER2-negative, estrogen receptor ɑ (ESR1)-mutated advanced or metastatic breast cancer (345 mg PO QD) based on progression-free survival (PFS) data from EMERALD (NCT03778931). As the first novel endocrine therapy approved in over 20 years and the first approved oral SERD, the drug marks an inflection point in the exciting and highly competitive pursuit of oral SERDs and a milestone for breast cancer treatment in general. The drug’s activity against difficult-to-treat ER-mutant tumors, thanks to a novel binding mode, allows it to improve survival among patients with ESR1-mutations detected in the ligand-binding domain via a circulating tumor DNA (ctDNA) companion…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: